News about Clinical Trials

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck Ends Phase 3 Development of Investigational BTK Inhibitor Nemtabrutinib

Merck discontinues the clinical development of nemtabrutinib and all three Phase 3 BELLWAVE trials following a benefit-risk assessment that raised concerns about the investigational BTK inhibitor.

Clinical Trials | 20/11/2026 | By News Bureau

GSK Receives US FDA Accelerated Approval for Nelkarmi in ALK-Positive Lung Cancer

GSK Receives US FDA Accelerated Approval for Nelkarmi in ALK-Positive Lung Cancer

GSK receives US FDA accelerated approval for Nelkarmi to treat adults with previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer.

Clinical Trials | 19/11/2026 | By News Bureau

EktaH Advances NKS-3 into Phase 2 Trials for Obesity Treatment

EktaH Advances NKS-3 into Phase 2 Trials for Obesity Treatment

EktaH has enrolled the first patient in its Phase 2a SERENITY-1 study evaluating oral candidate NKS-3 for obesity treatment in Tunisia.

Clinical Trials | 17/11/2026 | By News Bureau

Evotec Secures USD 2.9 Million Gates Foundation Grant for Foetal Safety Research

Evotec Secures USD 2.9 Million Gates Foundation Grant for Foetal Safety Research

Evotec SE receives a USD 2.9 million grant from the Gates Foundation to extend its human stem cell-based NAMs research for another three years.

Clinical Trials | 17/11/2026 | By News Bureau

Arga Medtech Completes Enrolment in COHERENT-AF PAF Cohort

Arga Medtech Completes Enrolment in COHERENT-AF PAF Cohort

Argá Medtech has completed enrolment of 150 participants in the paroxysmal atrial fibrillation cohort of its COHERENT-AF study, which is evaluating the CSE Platform for cardiac arrhythmias.

Clinical Trials | 13/11/2026 | By News Bureau

EIT Pharma Advances Lonafarnib Development with Extended Phase 3 Data

EIT Pharma Advances Lonafarnib Development with Extended Phase 3 Data

EIT Pharma presented extended analyses from its Phase 3 D-LIVR trial at The Liver Meeting, highlighting durable treatment responses following the cessation of lonafarnib-based therapy in chronic hepatitis D.

Clinical Trials | 13/11/2026 | By News Bureau

Johnson & Johnson Reports Positive Phase 3 Results for Icotyde in Psoriatic Arthritis

Johnson & Johnson Reports Positive Phase 3 Results for Icotyde in Psoriatic Arthritis

Johnson & Johnson reported positive Phase 3 results for Icotyde, an oral IL-23 receptor-targeting peptide being investigated for the treatment of psoriatic arthritis.

Clinical Trials | 10/11/2026 | By News Bureau |  116

Akeso's Ivonescimab Receives Priority Review in China for Biliary Tract Cancer

Akeso's Ivonescimab Receives Priority Review in China for Biliary Tract Cancer

Akeso's ivonescimab has received Priority Review from China's NMPA for first-line treatment of locally advanced or metastatic biliary tract cancer.

Clinical Trials | 06/11/2026 | By News Bureau |  123

Acepodia Doses First Patient in Phase 1 Trial of ACE723 for Liver Cancer

Acepodia Doses First Patient in Phase 1 Trial of ACE723 for Liver Cancer

Acepodia has dosed the first patient in its Phase 1 clinical trial of ACE723, an investigational dual-payload ADC for unresectable or metastatic hepatocellular carcinoma.

Clinical Trials | 06/11/2026 | By News Bureau |  131

TRANSFORM 2 Trial Shows Sirolimus-Coated Balloon Matches Drug-Eluting Stents

TRANSFORM 2 Trial Shows Sirolimus-Coated Balloon Matches Drug-Eluting Stents

TRANSFORM 2 trial found Concept Medical’s MagicTouch sirolimus-coated balloon non-inferior to drug-eluting stents, demonstrating comparable 12-month outcomes in 1,842 patients with coronary artery disease.

Clinical Trials | 06/11/2026 | By News Bureau |  121

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members